TNM-009

The primary objective of this study is to evaluate the safety and tolerability of TNM009 injection (hereinafter referred to as TNM009) after a single subcutaneous (SC) or intravenous (IV) administration in healthy adult subjects; the secondary objective is to evaluate the pharmacokinetic (PK) characteristics of TNM009 after a single SC or IV administration in healthy adult subjects; to evaluate the absolute bioavailability of TNM009 after a single SC administration in healthy adult subjects; to evaluate the immunogenicity of TNM009 after a single SC or IV administration in healthy adult subjects; the exploratory objective is to evaluate the effect of a single SC or IV administration of TNM009 on the level of nerve growth factor in healthy adult subjects.